www.finanznachrichten.de ·
68484177 milestone pharmaceuticals inc milestone pharmaceuticals announces first quarter 2026 financial results and provides corporate update 399
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedMilestone Pharmaceuticals is a biotech company with a newly launched product CARDAMYST for PSVT. The commercial mechanism is early-stage: initial prescription uptake and formulary access indicate revenue potential but no significant margin or supply chain impact yet. The company is also initiating a Phase 3 trial for AFib-RVR, which is a pipeline event. No direct commodity or supply chain scarcity is involved.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Milestone Pharmaceuticals reported Q1 2026 net loss of $26.1M vs $20.8M prior year.
- Launched CARDAMYST (etripamil) nasal spray for PSVT in mid-February 2026.
- Approximately 600 prescriptions filled for 560 patients by April 2026.
- Secured national formulary coverage from Express Scripts.
- Cash balance $184.2M, expected to fund operations into H2 2027.
CARDAMYST revenue ramp is gradual; therefore, PHARMA_BIOTECH is affected flat. Key risk: if new formulary wins do not materialize or prescription growth stalls.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid